GPT and non-small cell lung carcinoma: Although Crizotinib has demonstrated effectiveness and good tolerability in ROS1-positive NSCLC patients without major adverse events, the most commonly observed adverse reactions are elevated aspartate/alanine aminotransferases (AST/ALT) and visual impairment [115].